Pasithea Therapeutics Corp. (NASDAQ:KTTA) Stock Short Interest Climbs 121.5%

Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 386,722 shares, a growth of 121.5% from the October 15th total of 174,598 shares. Based on an average daily trading volume, of 459,545 shares, the short-interest ratio is presently 0.8 days. Currently, 1.2% of the company’s stock are sold short.

Institutional Trading of Pasithea Therapeutics

An institutional investor recently bought a new stake in Pasithea Therapeutics stock. Opaleye Management Inc. bought a new position in shares of Pasithea Therapeutics Corp. (NASDAQ:KTTA – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,050,000 shares of the company’s stock, valued at approximately $1,057,000. Opaleye Management Inc. owned about 6.14% of Pasithea Therapeutics at the end of the most recent quarter. 23.92% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Monday, September 21st. Zacks Research downgraded shares of Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Pasithea Therapeutics currently has an average rating of “Hold” and an average target price of $3.00.

Get Our Latest Stock Analysis on Pasithea Therapeutics

Pasithea Therapeutics Price Performance

Shares of NASDAQ:KTTA opened at $0.52 on Monday. The business’s 50-day moving average is $0.48 and its 200 day moving average is $0.61. Pasithea Therapeutics has a 1 year low of $0.28 and a 1 year high of $2.06. The firm has a market capitalization of $17.44 million, a P/E ratio of -0.38 and a beta of 0.39.

Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. On average, analysts expect that Pasithea Therapeutics will post -0.76 EPS for the current year.

About Pasithea Therapeutics

(Get Free Report)

Pasithea Therapeutics is a clinical-stage biotechnology company developing therapies for serious diseases. Its current focus is PAS-004, a next-generation macrocyclic MEK inhibitor being studied for conditions associated with the RAS/MAPK signaling pathway, including neurofibromatosis type 1. The company’s research has shifted over time: Pasithea previously focused on treatments for neurological and psychiatric disorders. Its current development efforts are centered on PAS-004 and potential applications in diseases with limited treatment options.

See Also

Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.